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Immunization with a T cell–dependent antigen elicits production of specific memory B cells 
and antibody-secreting cells (ASCs). The kinetic and developmental relationships between 
these populations and the phenotypic forms they and their precursors may take remain 
unclear. Therefore, we examined the early stages of a primary immune response, focusing on 
the appearance of antigen-specific B cells in blood. Within 1 wk, antigen-specific B cells 
appear in the blood with either a memory phenotype or as immunoglobulin (Ig)G1 ASCs 
expressing 
 
blimp-1
 
. The memory cells have mutated V
 
H
 
 genes; respond to the chemokine 
CXCL13 but not CXCL12, suggesting recirculation to secondary lymphoid organs; uniformly 
express B220; show limited differentiation potential unless stimulated by antigen; and 
develop independently of 
 
blimp-1
 
 expression. The antigen-specific IgG1 ASCs in blood show 
affinity maturation paralleling that of bone marrow ASCs, raising the possibility that this 
compartment is established directly by blood-borne ASCs. We find no evidence for a 
 
blimp-1
 
–expressing preplasma memory compartment, suggesting germinal center output is 
restricted to ASCs and B220
 
 
 
 memory B cells, and this is sufficient to account for the 
process of affinity maturation.
 
The immune response to protein-containing
antigen elicits quiescent memory B cells and
long-lived antibody-secreting cells (ASCs; for
review see reference 1). Memory B cells typi-
cally express Ig isotypes downstream of IgM
such as IgG or IgA, carry somatic mutations
within their variable (V) region genes that
preferentially exchange amino acids within the
CDR, and differentially express several cell
surface markers relative to naive B cells (2–4).
Although memory cells show some preference
for localization at the site of their formation,
they also recirculate (5) and mount a vigorous
response to the original antigen after reexpo-
sure. In contrast, the population of long-lived
ASCs maintains serum titres of high affinity
antigen-specific antibody over extended periods
(6–8), while neither recirculating nor responding
to antigen in any discernible way (9). These
cells also differ phenotypically from naive B
cells, usually through the down-regulation of
surface markers such as CD19, B220, and
MHCII (7, 9). Although memory B cells and
bone marrow ASCs have been identified as
having a common origin in the germinal center
(GC), the means by which these compart-
ments are established from B cells that emi-
grate from the GC remains poorly understood
(10, 11).
One model for the formation of the memory
compartment (12) proposes that high affinity
antibody secreted by GC-derived ASCs feeds
back into the GC reaction, competing with
centrocytes for binding to antigen localized on
the surface of follicular DCs. This infers that
formation of a high affinity population of
ASCs (now known to reside primarily in the
bone marrow) should precede formation of
the memory compartment, which agrees with
the limited data available on the kinetics of the
formation of these two post-GC populations
in spleen (10, 11, 13).
The formation of the bone marrow plasma
cell populations is also ill-defined. Although it
is clear that the vast majority of ASCs in bone
marrow are GC derived (10, 11), the means by
which they are selected for this fate and the
processes of their migration and persistence re-
main unclear. Two proposals to explain ASC-
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precursor emigration from the GC are as follows: (a) BCR
cross-linking in the GC generates a signal that commits cen-
troblasts to ASC differentiation (14); and (b) bone marrow
ASC formation has a post-GC period of clonal selection
(11). Neither of these models address the form that GC cells
committed to being bone marrow ASCs assume during mi-
gration. The bone marrow compartment could be seeded by
precursor cells that differentiate upon arrival or alternatively
by functional ASCs. Evidence in support of both proposals
has been reported, although not with universal acceptance
(15). In mice, nonsecreting plasma cell precursor populations
have been identified that derive from the GC, retain surface
Ig yet lose B220, and, in a recent paper, show an absolute
dependence on the plasma cell commitment factor, Blimp-1
(16–19). Alternatively, ASCs have been detected in blood
after secondary immunization (20–22), which in humans
show a phenotype suggesting they are part of a developmen-
tal program ending in bone marrow ASCs (21, 23).
An analysis of GC output from a defined starting point
may assist in clarifying the origin and development of the
post-GC, effector B cell populations. In this paper, we ex-
amine GC output in mice after a single immunization by as-
sessing the appearance and composition of antigen-specific B
cells in the blood. We identify cells with characteristics of ei-
ther memory or ASC lineages in blood and examine their
cellular and molecular characteristics. These data suggest
both the criteria involved in the selection of GC B cells for
emigration and the possible fate of such émigrés. These re-
sults have important implications for the regulation of the
GC reaction, the mechanism of immunological memory for-
mation, and the establishment of the bone marrow ASC
compartment.
 
RESULTS
Antigen-specific B cells in blood appear early, persist, 
and are B220
 
 
 
To characterize the development of the post-GC antigen-
specific B cell populations, we examined blood for the pres-
ence of cellular intermediaries. Animals were examined ini-
tially 7 d after primary immunization and had blood and
spleens harvested, and leukocytes were recovered and parti-
tioned into populations of cells that did and did not stain
with a cocktail of antibodies comprising CD138, Gr-1, F4/
80, and both IgM and IgD (Fig. 1 A). Among the negative
population, cells were identified that expressed IgG1 and
bound the immunizing hapten, (4-hydroxy-3-nitrophe-
nyl)acetyl (NP), coupled in this case to allophycocyanin.
Small populations of such cells were seen in both spleen and
blood (Fig. 1), and their presence was found to be dependent
on immunization with NP-containing antigen. Upon exam-
ination, the NP
 
 
 
IgG1
 
 
 
 cells were found to be uniformly
positive for B220, in contrast with previous analyses (16). In-
terestingly, the level of B220 on blood NP-specific cells was
consistently lower than that of naive B cells and NP-specific
IgG1
 
 
 
 B cells in spleen, although the significance of this ob-
servation remains unclear. Therefore, it appears that, with
the immunization protocol used in this work, the vast ma-
jority of the IgG1
 
 
 
 antigen-specific cells express detectable
levels of B220. We examined the kinetics of the formation
of B220
 
 
 
NP
 
 
 
IgG1
 
 
 
 B cells in blood after a single immuni-
zation, determining their time of appearance and persistence
(Fig. 1 B). At regular intervals after primary i.p. immuniza-
tion, animals were killed and their spleens and blood were
examined. Before day 6, no NP-binding IgG1
 
 
 
 cells were
detectable in either blood or spleen, but having appeared,
Figure 1. Identification of antigen-specific B cells in blood. (A) Leu-
kocytes recovered from the spleen and blood of mice immunized 7 d pre-
viously were partitioned using flow cytometry into those expressing and 
not expressing (boxed) a collection of markers, referred to as the Dump-
channel: IgM, IgD, Gr-1, and F4/80. Among negative cells, those that had 
switched isotype to IgG1 and were capable of binding the immunizing 
hapten were detected by IgG1-specific anti-sera and NP coupled to the 
fluorescent protein allophycocyanin, revealing a predominant IgG1  NP-
binding population (boxed). Examining the IgG1 NP  cells in both spleen 
and blood revealed these cells to be essentially all B220 , shown in com-
parison to the B220 distribution on all leukocytes (histograms). Mice im-
munized with KLH in alum do not develop IgG1 NP  cells in either blood 
or spleen (lower contours, already gated as Dump ). (B) The kinetics of 
B220 IgG1  NP-binding B cells in blood and spleen after primary immu-
nization. Blood and spleen from individual mice were collected at the indi-
cated intervals after a single i.p. immunization and the proportion of 
B220  NP-binding IgG1  cells determined by flow cytometry as depicted 
in A. The plot shows the average of each tissue with the standard devia-
tion. n   3 mice for each time point. Significant differences as calculated 
by Student’s t test are indicated. *, P   0.01; **, P   0.001. 
JEM VOL. 201, February 21 , 2005
 
547
 
ARTICLE
 
antigen-specific B cells remained detectable in blood for the
next 5 wk, the duration of the analysis. The frequency of
these B cells in blood varied little over the experimental pe-
riod, suggesting either a stable population or continued out-
put during the time course of the experiment. Although in
the early stages of the response, B220
 
 
 
NP
 
 
 
IgG1
 
 
 
 B cells
were significantly more common in spleen than in blood, by
21 d after immunization, this difference was no longer ap-
parent (Fig. 1 B). Collectively, these data demonstrate the
rapid appearance and subsequent persistence of isotype-
switched, antigen-specific B220
 
 
 
 B cells in blood after a sin-
gle i.p. immunization.
 
B220
 
 
 
 antigen-specific B cells in blood have 
a memory phenotype
 
Next, we examined the expression of additional cell surface
markers on NP
 
 
 
IgG1
 
 
 
 cells in blood. At days 7 and 14 after
immunization, B220
 
 
 
 cells were purified from blood and
spleen using B220-specific magnetic bead separation, which
consistently produced 
 
 
 
99% purity as defined by CD19 ex-
pression. The purified B220
 
 
 
 cells were stained with IgM
and IgD to exclude naive B cells, IgG1 and NP-allophyco-
cyanin, to reveal the antigen-specific B cells and an addi-
tional reagent to examine the expression level of various
markers in comparison with naive B cells from the same lo-
cation. The B220
 
 
 
NP
 
 
 
IgG1
 
 
 
 cells in spleen and blood ex-
pressed CD19 at levels equal to naive B cells at all times.
However, expression of CD38 and binding of the lectin
PNA varied between locations. On days 7 and 14, 
 
 
 
80% of
B220
 
 
 
NP
 
 
 
IgG1
 
 
 
 cells in spleen had a GC phenotype (Fig.
2), defined as CD38
 
lo
 
 and PNA
 
hi
 
 (13). However, in blood,
the majority of B220
 
 
 
NP
 
 
 
IgG1
 
 
 
 cells at these same time
points had the reciprocal memory phenotype, CD38
 
hi
 
 and
PNA
 
lo
 
 (Fig. 2), a phenotype retained at later time points.
Furthermore, the NP-specific IgG1
 
 
 
 cells in both spleen and
blood were physically larger than their naive B cell counter-
parts as measured by forward light scatter, consistent with
antigen-mediated activation (unpublished data). Neither
CD138 nor CD11c were detected on B220
 
 
 
NP
 
 
 
IgG1
 
 
 
cells in the blood, but these cells did express CD86 at low
levels (unpublished data). We conclude that the blood is en-
riched from very early after immunization for isotype-
switched antigen-specific B cells with cell surface character-
istics of memory B cells.
 
NP
 
 
 
IgG1
 
 
 
 blood B cells accumulate V
 
H
 
 gene 
somatic mutations
 
A characteristic of GC-derived B cells is the modification of
Ig V region genes by somatic mutation and the subsequent
enrichment for amino acid exchanges that enhance affinity.
To assist in identifying the developmental origin of the blood
NP
 
 
 
IgG1
 
 
 
 cells, we amplified rearranged V
 
H
 
186.2-C
 
 
 
1
cDNA from single B220
 
 
 
NP
 
 
 
IgG1
 
 
 
 cells sorted from blood.
These PCR products were sequenced to verify the identity of
the V
 
H
 
 gene and to define the frequency and distribution of
somatic mutations (Table I). Blood sequences from different
times in the response were compared with the equivalent V
 
H
 
sequences obtained from NP-specific B cells isolated from
spleen over the same period. First, we note that the overall
recovery of V
 
H
 
-C
 
 
 
1 products from single cell cDNAs was
essentially equal in blood (52 
 
 
 
 15.5%) and spleen (58 
 
 
 
12.6%). Second, the proportion of these PCR products sub-
sequently confirmed to contain V
 
H
 
186.2 was again equal be-
tween blood (84 
 
 
 
 7.3%) and spleen (80 
 
 
 
 9.2%). These
data, shown for individual time points in Table I, indepen-
dently support the flow cytometric identification of the NP-
binding population in blood as being B cells and being NP
specific. We examined the sequences for the appearance, dis-
tribution, and frequency of somatic mutations. At day 7, we
found an average of 1.8 mutations/V
 
H
 
 gene in spleen
NP
 
 
 
IgG1
 
 
 
 B cells. However, the corresponding blood sam-
ple contained significantly fewer mutations both on average
(0.1 mutations/V
 
H
 
 gene) and in the proportion of mutated
sequences (Table I). Cells recovered at days 10 and 14
showed an increasing frequency of mutations in both blood
and spleen, although the frequency in blood was typically less
than that of contemporaneous spleen (Fig. 3 A and Table I).
By day 28, the average frequency of mutations was approxi-
mately equal in both groups. The somatic mutations in the
V
 
H
 
 genes of antigen-specific B cells in blood indicates a GC
origin, whereas the increasing frequency of both mutation
and proportion of mutated sequences in a numerically stable
population (Fig. 1 B) indicates turnover of the population.
Assessing the location of specific mutations in the V
 
H
 
genes from blood and spleen gave further insights into the
development of these B cells (Fig. 3 B and Table I). We
found that the tryptophan to leucine exchange at position 33
of the heavy chain that typifies affinity maturation in the
Figure 2. The cell surface phenotype of B220  NP-binding IgG1  
cells in blood and spleen 7 and 14 d after immunization. B220  cells 
were purified mechanically from spleen and blood and stained for surface 
IgM, IgD, IgG1, and NP. The stains of spleen and blood (IgM, IgD)  B cells 
shown in the left column depict before separation, whereas those of 
NP IgG1  B cells depict after separation. Boxed areas indicate the cells 
analyzed for the parameters depicted by the histograms. The fourth parameter 
in these analyses is indicated above each column. The dashed line provides 
a point of reference for comparing samples. The cells were recovered from 
tissues pooled from two to four mice, and these data are representative of 
three separate experiments. Ctrl, isotype control antibody. 
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anti-NP response of C57BL/6 mice (24) appeared in blood
B cells at approximately day 10 and increased in representa-
tion over time until it reached a plateau by approximately
day 28. The frequency of this mutation in spleen NP-spe-
cific B cells was consistently similar to that in the blood pop-
ulation, increasing in parallel early and reaching a similar pla-
teau late in the response (Fig. 3 B). However, relative to the
overall mutational load, the position 33 replacement was
overrepresented in blood compared with spleen, suggesting
an enrichment for such cells in this location.
 
B220
 
 
 
NP
 
 
 
IgG1
 
 
 
 cells respond to CXCL13 but not CXCL12
 
The appearance of NP-specific B cells in blood early after
immunization raises questions concerning their fate. Such
cells could either be memory or ASC precursors. A feature
of B cell differentiation during an immune response is an al-
teration in chemokine responsiveness. Cells within the ASC
lineage acquire responsiveness to CXCL12 (25, 26), which
distinguishes them from cells in the GC (27). Therefore, we
sought to use chemokine responsiveness as a marker of B cell
differentiation. Leukocytes were prepared from blood and
spleen of mice immunized 14 d previously and added to the
upper well of Transwell chambers. The level of chemotaxis
of B cell subsets toward CXCL12 and CXCL13 was deter-
mined using flow cytometry to assess the number of cells
that had migrated through the membrane. Thus, migrating
cells were assessed for the presence of B220
 
 
 
IgG1
 
 
 
NP
 
 
 
 cells
and this number was calculated as a percent of such cells
originally placed in the upper well (Table II). We observed
strong chemotaxis of antigen-specific IgG1
 
 
 
 B cells toward
CXCL13 and essentially none toward CXCL12 (Table II).
The propensity of blood-borne NP-specific B cells to mi-
grate toward the follicular chemokine and a corresponding
lack of attraction to the bone marrow chemokine suggests a
migratory route that returns these B cells to the follicles of
secondary lymphoid organs.
 
Differentiation potential of blood leukocytes upon transfer
 
Next, we assessed the developmental potential of blood-
borne antigen-specific B cells after transfer into recipients
with or without antigen boost. These experiments used
 
CD19
 
   
 
 mice as recipients, as they do not produce IgG1
ASCs in the bone marrow after immunization with antigen
in alum (references 28, 29 and unpublished data). Transfer of
blood leukocytes from mice immunized 14 d previously
with NP-KLH in alum resulted in few ASCs appearing in
the recipients’ bone marrow or spleen 4 d later (Fig. 4). We
recovered an average of 0.5 NP-specific IgG1 ASCs per 10
 
7
Figure 3. Evidence for somatic mutation and affinity maturation 
in blood NP IgG1  B cells. Single NP-binding IgG1  B cells were iso-
lated from blood and spleen at the indicated times (for details, see Table I). 
Analysis of those VH-C 1 rearrangements using VH186.2 provided the 
values depicted in this figure. (A) The average mutation frequency of VH 
genes at the indicated times is plotted against the time after immuniza-
tion. The dashed line indicates the time difference between the two popu-
lations required to reach an average of 2.0 mutations per VH gene. Accu-
mulation of mutations in blood cells is delayed by  2.5 d compared with 
spleen. (B) The proportion of VH sequences in blood and spleen NP-specific 
IgG1  B cells containing a position 33 Y → L exchange as a function of 
time. Unlike the mutation frequency, cells bearing affinity-enhancing 
mutations are almost as common in blood as in spleen at each time point. 
In both plots, spleen values use square symbols, whereas blood uses dia-
monds. Cells were recovered from tissues pooled from  6 mice at each 
time point.
 
Table I.
 
V
 
H
 
 gene somatic mutation among NP-specific B cells in 
blood and spleen
 
Day
 
a
 
Tissue PCR
 
 
 
b
 
V
 
H
 
186.2
 
c
 
Mutation
(average)
 
d
 
Germline Position 33
% % Y → L
7
spleen 21/45 16/21 1.8 25 0
blood 22/35 21/22 0.1 95 5
10
spleen 55/80 50/55 2.7 12 50
blood 54/188 45/54 1.2 47 37
12
spleen ND ND ND ND ND
blood 27/40 24/27 2.4 33 58
14
spleen 35/80 30/35 4.4 3 67
blood 37/97 29/37 2.3 7 48
28
spleen 43/60 29/43 5.8 7 45
blood 28/45 21/28 4.4 28 48
aMice were killed at the indicated times after immunization and individual 
B220 NP IgG1  cells were sorted by flow cytometry. Three to eight mice were used 
per experiment with samples pooled before sorting. Data are from at least two ex-
periments per time point.
bThe number of successful PCR amplifications of VH186.2-C 1 rearrangements from 
single cell cDNA as a fraction of the number of reactions.
cThe number of amplified VH186.2-C 1 rearrangements confirmed to contain the 
unique hexamer as a fraction of all sequences.
dAverage mutation frequency, percent germline sequences, and percent of se-
quences containing tryptophan to leucine exchange at VH position 33 are for all 
VH186.2 sequences recovered.JEM VOL. 201, February 21 , 2005 549
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recipient bone marrow cells (Fig. 4), equating to  24 such
ASCs in the whole animal, given that adult C57BL/6 mice
contain 47   107 bone marrow cells (30), with an additional
50 such ASCs in spleen (Fig. 4). Because the 107 donor cells
contained 103 B220 NP IgG1  B cells based on these cells
being 0.01% of the population (Fig. 1 B), these data imply
that  10% of the B220  NP-specific population spontane-
ously differentiated into ASCs if this were the ASC precur-
sor population. The possibility that the ASCs appearing in
the recipient arose from an alternative precursor population
in blood cannot be excluded (see next paragraph). Next, we
examined the potential of blood B cells from NP-KLH im-
munized mice to respond to reexposure to antigen. In this
case, CD19    recipients were primed with human serum
albumin (HSA) in alum 14 d before cell transfer from NP-
KLH immunized donors. Recipients were boosted with
NP-HSA at the time of transfer and, 4 d later, the frequency
of NP-specific IgG1 ASCs was determined in the recipients’
spleens (Fig. 4). This experiment revealed memory potential
in the donor blood leukocytes, in that we observed a signifi-
cant expansion in the number of NP-specific IgG1 ASCs in
the spleens of the recipients after antigen boost (Fig. 4). Col-
lectively, these experiments demonstrate the presence of
functional memory B cells in the blood of mice immunized
14 d previously, yet also indicate that there are rare cells in
the blood capable of generating ASCs in the bone marrow
without deliberate stimulation.
Affinity-matured ASCs appear in blood
The apparently limited potential of blood leukocytes to
generate bone marrow ASCs upon transfer, coupled with
the lack of CD138 expression and chemokine sensitivity of
the B220 NP IgG1  population, made it unlikely that
these cells were committed to the bone marrow ASC com-
partment. This left the origin of the bone marrow ASCs un-
clear. This issue was investigated using a recently developed
reporter mouse that has GFP targeted to the blimp-1 locus
(31). In such blimp-1gfp/  mice, cells committed to ASC dif-
ferentiation as defined by expression of blimp-1 (32) are de-
tectable by flow cytometry for GFP expression in both
spleen and bone marrow (Fig. 5 A). After immunization,
cells sorted from these locations on the basis of GFP contain
NP-specific IgG1 ASCs (Fig. 5 C and reference 31). There-
fore, we examined blood at various times after immuniza-
tion for the presence of ASCs using blimp-1gfp as a marker.
Such a population, expressing simultaneously blimp-1gfp and
CD138, was found in unimmunized mice and changed little
in frequency after immunization (Fig. 5, A and B). Identifi-
cation of these cells in blood allowed us to examine the
composition of the population with respect to NP-specific
ASC activity and affinity. Cells sorted as blimp-1gfp CD138 
from mice immunized 0, 7, or 14 d previously were plated
in ELISPOT assays to enumerate NP-specific IgG1 ASCs.
Such activity was found within the sorted populations in
spleen, blood, and bone marrow only after immunization
(Fig. 5 C and reference 31). In spleen, the relative and abso-
lute frequency of IgG1  NP-specific ASCs, both in total
and high affinity, declined between 7 and 14 d after immu-
nization, in agreement with previous papers (7). However,
the proportion of ASCs in spleen secreting high affinity
IgG1 increased from 30 to 60% over this period. In con-
Table II. Chemotaxis of blood-borne NP-specific B cells
Migration as a percentage of inputa
Chemokineb B220 IgMIgD  B220 IgMIgD  B220 NP IgG1  Non–B cells
%% % %
None 0.09   0.01 0.70   0.14 0 0.95   0.07
CXCL13 8.8   1.6 2.9   0.7 15.0   4.1 1.8   0.3
CXCL12 7.8   6.1 4.8   4.0 0.6   0.8 5.3   3.0
aCell populations were enumerated by flow cytometry before and after migration. The number migrating through the membrane is expressed as a fraction of input cells of that 
phenotype. Data are from two experiments each using four wells (CXCL13) and two wells (CXCL12). 
bCXCL13 present at 800 ng/mL; CXCL12 present at 400 ng/mL.
Figure 4. Blood leukocytes from immunized mice respond to antigen 
in the presence of T cell help. Leukocytes were purified from the pooled 
blood or spleen of six mice immunized 14 d previously with NP-KLH. 107 
of these cells were transferred to mice previously primed with a single 
injection of HSA in alum. Recipients were either left untreated or boosted 
with NP-HSA as indicated. 4 d after transfer, recipients were killed and the 
frequency of NP-specific IgG1 ASCs determined in bone marrow or spleen 
are indicated. The horizontal bar shows the average for each condition. 
The resolution of this assay was 0.1 IgG1 ASCs per 106 plated cells. The 
number of recipients assessed for each condition is indicated. No NP-
specific IgG1 ASCs were detected in either the absence of transferred cells 
or after transfer of leukocytes from naive mice (not depicted).GERMINAL CENTER ÉMIGRÉS IN BLOOD | Blink et al. 550
trast, the frequency of both total and high affinity IgG1 NP-
specific ASCs increased in bone marrow between 7 and 14 d
after immunization, reflecting the recruitment of high affin-
ity ASCs to this location (Fig. 5 C). In blood, although the
overall frequency of NP-specific IgG1 ASCs declined be-
tween days 7 and 14, that of high affinity ASCs increased
(Fig. 5 B). Therefore, the ASCs in the blood may serve as a
repository from which the bone marrow ASC compartment
is recruited.
Blimp-1 is not expressed in CD138 NP IgG1  cells
Up to this point, our data describe B220 IgG1  antigen-spe-
cific memory B cells in blood and spleen and CD138 Blimp-
1  ASCs in blood, spleen, and bone marrow that include
IgG1 anti-NP activity. Previously, another population of
GC-derived, antigen-specific but B220  B cells that were lo-
calized in spleen and bone marrow and predisposed to gener-
ate ASCs upon restimulation has been identified (16). Mice
lacking blimp-1 produce very little serum antibody after im-
munization and lack B220  memory cells despite retaining
B220  memory (19). These results have been interpreted to
mean that blimp-1 expression is required for the development
of both ASCs and a B220  preplasma memory compartment
(19, 33). We examined immunized blimp-1gfp/  mice for the
presence of NP IgG1  cells that were CD138  yet Blimp-1 
as predicted by analysis of the immune response in blimp-1   
mice (19, 33). This analysis revealed a clear population of
CD138 NP IgG1  cells in the spleen at day 14 after immu-
nization but  1% of these cells expressed Blimp-1 (Fig. 6).
This is also despite the presence of CD138 Blimp-1  ASC
populations in the spleen, blood, and bone marrow of these
same mice (Fig. 5). Thus, in this experimental set-up, blimp-1
expression within the B lineage is restricted to active ASCs
and does not occur in other antigen-specific B cells, irrespec-
tive of their B220 status.
Figure 5. ASCs in blood after immunization revealed by expression 
of blimp-1. (A) Mice with GFP targeted to one allele of the blimp-1 locus 
were immunized, and blood, spleen, and bone marrow were collected at 
the indicated times. Flow cytometric analysis of leukocytes revealed popu-
lations of GFP CD138  cells in all tissues. (B) The frequency of such cells 
in individual mice is indicated as a percentage of total blood leukocytes 
for the different tissues. Data from spleen and bone marrow have been 
reported previously (reference 31) and are shown here for comparative 
purposes only. (C) GFP CD138  cells were purified by sorting and assessed 
for the frequency of NP-binding IgG1 ASCs, comparing spleen, blood, and 
bone marrow populations from the same times. In each case, 500 sort-
purified cells were placed in ELISPOT wells coated with either high or low 
haptenated proteins to detect total or high affinity NP-specific IgG1 ASCs, 
respectively. The number of spots of each type is plotted and represents 
the average compiled from four experiments at day 14 and three at day 7, 
each experiment using tissue pooled from two to four mice. The number 
of total IgG1 anti-NP ASCs per 500 sorted cells is indicated by the
height of the column and the number of high affinity ASCs by the striped 
section of each column. Unimmunized mice (n   3) showed no NP-
specific IgG1 ASCs in any location. The proportion of total ASCs with high 
affinity is calculated as NP2/NP17 ASCs. The change in ratio between days 
7 and 14 within each population is significantly different (P   0.05, Stu-
dent’s t test) although the differences between populations at each time 
are not significantly different.
Figure 6. CD138-NP IgG1  cells appearing in spleen do not express 
blimp-1. blimp-1gfp/  heterozygous mice were immunized with NP-KLH in 
alum and 14 d later examined for the appearance in the spleen of NP-
specific IgG1  B cells that lacked expression of CD138 in addition to other 
Dump-channel markers (IgM, IgD, Gr-1, F4/80). However, among these 
NP IgG1  cells, none were found to express blimp-1 as indicated by the 
absence of GFP  cells in the gate. One out of two representative experi-
ments is shown.JEM VOL. 201, February 21 , 2005 551
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DISCUSSION
The output of the GC reaction is well defined; it is responsi-
ble for the production of a recirculating memory B cell pop-
ulation and a long-lived population of ASCs located primar-
ily in the bone marrow. These populations are enriched,
albeit to varying degrees (10), for cells with improved bind-
ing to antigen due to the preferential expansion of clones in
the GC with appropriate V gene somatic mutations. How-
ever, beyond this descriptive statement, little can be said re-
garding the mechanism by which the memory and ASC
compartments are formed. The data presented here address
this issue by examining in detail the nature of the cells emi-
grating from the GC during the early period after primary
immunization. We show that representatives of two B cells
lineages are detectable in blood, one with characteristics of
memory cells and the other of ASCs. The B cells with mem-
ory phenotype express B220 and contain V genes with so-
matic mutations consistent with a GC origin. We also find
cells in blood with an ASC phenotype in that they express
blimp-1 (a gene associated with commitment to ASC differ-
entiation; reference 32) and, when isolated, secrete antigen-
specific IgG1 that shows evidence of affinity maturation.
Collectively, our data support a model in which the GC re-
action is dynamic with continuous cell output and, even at
early stages in the reaction, this output takes the form of
ASCs and memory B cells.
GC emigrants with a memory phenotype have several
characteristics that provide insight to the GC reaction. First,
the cells are enriched for somatic mutations that enhance af-
finity for the immunizing antigen relative to the overall mu-
tation load when compared with the corresponding splenic
population. This enrichment represents  2 d of mutation
and selection in the GC reaction (Fig. 3) and suggests that af-
finity is a criterion for emigration. Second, the preferential
migration of these GC emigrants toward the follicular che-
mokine, CXCL13 (34), implies that the NP-specific B cells
in blood are likely to return to the follicles of secondary lym-
phoid organs, including spleen. These observations raise the
interesting possibility that GCs are open to immigration;
variants formed in one GC, for example, may be able to seed
other GC via the blood, thereby equilibrating affinity matu-
ration across the reaction.
The data presented here allow us to speculate on the
mechanism of memory formation. From early in the re-
sponse, the phenotype of the blood antigen-specific B cells
was similar to that of memory B cells (Fig. 3). They ex-
pressed levels of CD38 and bound levels of the lectin PNA
equal to that of naive B cells, both characteristics of memory
B cells and the inverse of GC B cells (13, 35, 36). That these
cells in blood are antigen experienced is supported by their
having isotype switched, being larger, and containing somat-
ically mutated VH genes. However, as the response pro-
gressed, the average mutational load of cells in the blood in-
creased, whereas the population size remained constant (Fig.
1 B). Thus, GC-derived B cells constantly entered the circu-
lation at the expense of existing cells in the blood. Further-
more, treatment at day 7 with antibodies that ablate CD4  T
cells, thus abrogating the GC reaction (37), resulted in a 50%
reduction in the B220 NP IgG1  cells in blood within 3 d
(unpublished data). Collectively, these data suggest that early
in the response, despite displaying a memory phenotype, the
majority of antigen-specific B cells in the blood have a lim-
ited life span and presumably either return to the GC or die.
However, a proportion of these cells may persist for some
time and it may be that the long-lived recirculating memory
B cell population is formed by a process of accumulation
over the duration of the response rather than in a single “big
bang” reaction. It will be of great interest to know whether
the retention of cells in the blood is stochastic or selective
and whether even at early time points there are a small num-
ber of long-lived cells among those already in the blood.
Such a process would account for the appearance of low af-
finity B cells in the memory compartment (10, 38).
Our rationale for examining blood was to identify a popu-
lation of cells capable of generating bone marrow ASCs.
Transferred blood leukocytes from day 14 immunized mice
showed very limited potential to differentiate unless simulta-
neously exposed to antigen in the presence of T cell help,
making the major population of NP-binding B cells inefficient
intermediates between the GC and the bone marrow ASCs.
Therefore, the observation of an ASC population in blood
raises the possibility of these cells being the precursors of the
bone marrow ASCs. We have yet to test this proposal by
transfer of ASCs isolated from blood as the rarity of these cells
currently precludes such experiments. If blood ASCs were to
give rise to the bone marrow ASCs, the formation of a bone
marrow population enriched for high affinity would not nec-
essarily require additional post-GC selection or differentiation,
as has been proposed (11, 16, 18). The data presented here
support the view that the formation of the bone marrow ASC
compartment is achieved by the retention of ASCs in the
bone marrow from among cells that emigrate from the GC as
ASCs. As the GC reaction proceeds, it becomes enriched for
high affinity variants. In vitro studies with both mouse and
human B cells show that under conditions mimicking T-depen-
dent stimulation, a proportion of the B cells will differenti-
ate into ASCs with each division (39, 40). Thus, the intrinsic
differentiation of GC centroblasts into ASCs that enter the
blood will result in an increasing fraction of these cells being
high affinity and thereby increasing the likelihood of high af-
finity ASCs being recruited into the bone marrow ASC com-
partment. In such a scheme, formation of the bone marrow
ASC compartment is stochastic and reflects directly the selec-
tive expansion of high affinity cells in the GC. This proposal
may explain phenomena associated with the formation of the
bone marrow ASCs (11, 14). For example, BCR signaling
strength could still influence affinity maturation by influencing
the composition of the blood borne ASC pool. Stopping the
GC reaction may not block further affinity maturation of the
bone marrow ASC compartment as it is drawn from post-GC
ASCs already in circulation. It will be of interest to examine
the blood ASCs in more detail for their lifespan and their de-GERMINAL CENTER ÉMIGRÉS IN BLOOD | Blink et al. 552
velopment in situations where affinity maturation is per-
turbed, as has been reported in Aiolos-deficient mice (41).
The blimp-1gfp reporter mouse will facilitate the identification,
isolation, and analysis of ASCs, allowing identification of the
factors responsible for their differentiation.
Exit of B cells from the GC has been the subject of sev-
eral investigations over many years. In an early analysis,
Baine and Thorbecke described transfer of antigen reactivity
from the contralateral lymph nodes of mice as early as 1 wk
after immunization (5). Our results suggest that these cells
emigrated from the GC of the ipsilateral (draining) lymph
nodes and represented part of the general recirculation of an-
tigen-specific B cells described here. A more recent analysis
examined GC emigration in a secondary response and found
PNAhi blasts in thoracic duct exudate and evidence for ASCs
in blood (20). Curiously, this activity peaked at day 3 after
boosting and was undetectable shortly thereafter. Similarly,
humans boosted with tetanus toxoid showed a surge in
CD38hi cells in blood that, as for the secondary response in
mice (20), peaked early after boosting and waned rapidly
(21). The systems described here will allow the clear resolu-
tion of this critical ASC population during both the primary
and secondary response as it overcomes a key previous diffi-
culty of unambiguously identifying ASCs.
Our data support a scheme whereby bone marrow ASCs
are derived from GC émigrés that are already ASCs rather
than a precursor yet to reach the stage of immunoglobulin se-
cretion (16, 18). We base this on the following five factors.
First, NP-specific ASCs with signs of affinity maturation are
present in blood during the period when the bone marrow
ASC compartment is being established. Second, there is no
evidence of a plasma cell precursor population as there are no
NP-specific cells expressing blimp-1 that are not active ASCs.
Third, previous reports of ASCs in blood after boosting of
immunized mice and humans (20, 21, 23) suggest these cells
are migratory with bone marrow as a destination. Fourth, i.v.
transfer of splenic plasma cells shows some to be retained in
bone marrow in a CXCR4-dependent process (26), indicat-
ing that blood-borne ASCs have the capacity to be retained
in the bone marrow. Finally, blimp-1–expressing cells have
been observed within GC (32), indicating that ASCs may
arise directly within such structures and subsequently migrate
through blood. Collectively, these analyses suggest that the
bone marrow ASC compartment is established by the migra-
tion through blood of cells committed to the ASC lineage
and actively secreting immunoglobulin. How these cells are
retained in the bone marrow is of considerable interest. It is
interesting to note that B cell niches in bone marrow are dis-
rupted transiently after the introduction of adjuvant (42), sug-
gesting there may be periods during which ASCs present in
the blood gain access to survival niches.
MATERIALS AND METHODS
Mice, antigens, and immunization. C57BL/6 mice were bred and
maintained in The Walter and Eliza Hall Institute of Medical Research and
used between 8 and 20 wk of age. All animal experimentation protocols
were approved by the relevant Animal Ethics Committee. Immunization
was with a single i.p. injection of 100  g NP coupled to KLH in the ratio of
13:1 and prepared as described previously (10), or in control experiments,
with 100  g KLH. The antigen was precipitated onto alum and washed ex-
tensively before injection. In some experiments, a secondary response was
elicited by intravenous injection of 20  g NP13-HSA suspended in PBS.
CD19    mice (28) were maintained in The Walter and Eliza Hall Institute
of Medical Research, and were originally a gift from K. Rajewsky (Harvard
University, Boston, MA). Construction of the blimp-1gfp reporter mouse is
described previously (31). In brief, an IRES-GFP construct was targeted to
exon 6 of the blimp-1 locus resulting in GFP expression coincident with that
of blimp-1. In vitro and in vivo experiments showed no difference in the rate
or frequency of differentiation of blimp-1gfp heterozygous B cells into ASCs
and all ASC activity lies in the GFP  cell fraction of heterozygous (blimp-1gfp/ )
mice (31). Lethally irradiated rag2    mice reconstituted with fetal liver cells
from homozygous blimp-1gfp/gfp mice showed a block in plasma cell develop-
ment and vastly reduced serum immunoglobulin titres consistent with a
complete loss of Blimp-1 function. Immunization experiments used mice 8
wk after reconstitution with either blimp-1gfp/gfp or blimp-1    fetal liver.
Tissue collection and cell preparation. Spleens and bone marrow were
recovered and prepared exactly as described previously (10). Blood was usu-
ally collected by cardiac puncture. Animals were asphyxiated with CO2 inha-
lation and, immediately after the cessation of breathing, had blood removed
by cardiac puncture into a heparin-containing syringe. Blood was underlayed
with Histopaque (Sigma-Aldrich) and centrifuged at 1,300 revolutions/min
at room temperature for 20 min. Leukocytes were collected from the inter-
face, washed extensively, and, where necessary, had residual red blood cells
removed by lysis in hypotonic buffer. In trial experiments, blood was sampled
from live mice by retro-orbital bleeding through heparin-coated capillary
tubes immediately before CO2 asphyxiation and blood collection by cardiac
puncture. Leukocytes from both blood samples were stained for NP-specific
B cells and compared with no difference in the frequency of such B cells be-
ing found in the two samples from any given individual, indicating that CO2
inhalation does not alter the B cell composition of the blood.
Antibodies, flow cytometry, cell sorting, and VH gene sequencing.
Single cell suspensions were stained as described previously (10) using the
following antibodies: B220 (RA3-6B2), IgM (331.12), IgD (11-26C), goat
anti–mouse IgG1 (Southern Biotechnology Associates, Inc.), Mac-1 (M1/
70), CD19 (1D3), CD86 (GL1), CD138 (281.1), CD8 (56–7.3), Gr-1, and
F4/80. FITC-peanut agglutinin (PNA) was purchased from Vector Labora-
tories. NP binding was detected using a conjugate of NP to allophycocya-
nin, made as described previously (43). Individual antigen-specific B cells
were sorted and processed for cDNA synthesis and VH gene PCR amplifi-
cation as described previously (44). Sequencing used ABI Prism Big Dye
Terminators v3.1 (Applied Biosystems), run on an Applied Biosystems
3730XL with automated base calling. Sequences identified as VH186.2 by
the presence of the hexamer AAACCC at VH73-74 (45) were compared
over their entire length to the defined VH186.2 germline sequence (46) to
identify the location and frequency of mutations.
Chemokine assay. Leukocytes from blood and spleen were incubated in
the upper compartment of 24-well HTS-Transwell chambers (Costar-
Corning) at a concentration of 4   105 cells/ml. Chemokines (Research
Diagnostics) were present in the bottom wells at concentrations of 800 ng/
ml (CXCL13) and 400 ng/ml (CXCL12). Plates were incubated for 4 h at
37 C, and the migrant cells in the bottom wells were collected and stained
as described before. Migration of antigen-specific B cells was assessed rela-
tive to the starting population and to random movement by flow cytometry
with a defined number of calibration beads added to each sample to stan-
dardize cell enumeration.
Cell transfer experiments. 14 d after immunization, mice were killed,
and blood and spleen were collected as described before. Single cell suspen-
sions were prepared and assessed for the frequency of NP-specific B cells byJEM VOL. 201, February 21 , 2005 553
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flow cytometry. After washing, the cells were resuspended in PBS at a con-
centration of 108 cells/ml and 100- l aliquots were injected i.v. into recipi-
ent mice. Recipient mice were CD19    (28), immunized 14 d previously
with HSA in alum. Some recipients were boosted at the time of transfer
with 20  g NP-HSA, injected i.p. in PBS. 4 d after cell transfer, recipient
mice were killed, and spleens and bone marrow were collected. The fre-
quency of IgG1  NP-specific ASCs was determined by ELISPOT assay us-
ing NP-BSA as a plate coat and conducted as described previously (10).
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